Shiirevnyamba Avirmed

Prof. Dr. Shiirevnyamba Avirmed

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Urology
Verified
Journal Article
Closed access
HTHisaya Takahashi
Hisaya Takahashi
HNHiroyoshi Nakatsuji
Hiroyoshi Nakatsuji
MTMasayuki Takahashi
Masayuki Takahashi
SAShiirevnyamba Avirmed
Shiirevnyamba Avirmed
TFTomoya Fukawa
Tomoya Fukawa
HKHiroomi Kanayama
Hiroomi Kanayama

1 January 2010 in The Journal of Medical Investigation
Verified
Journal Article
Open access
PDF file
MSManabu Sakaki
Manabu Sakaki
TFTomoharu Fukumori
Tomoharu Fukumori
TFTomoya Fukawa
Tomoya Fukawa
EEEssam Elsamman
Essam Elsamman
SAShiirevnyamba Avirmed
Shiirevnyamba Avirmed
HKHiro-Omi Kanayama
Hiro-Omi Kanayama
Overexpression of galectin-3 in a variety of cancer cell lines has been shown to correlate with tumor progression and metastasis. In this study, we investigated the expression of galectin-3 in clear cell renal cell carcinoma (CC-RCC) and evaluated the relationship between galectin-3 expression levels and the clinicopathological features of CC-RCC. Expression of galectin-3 in the kidney cancer cell lines Caki-1, Caki-2, A704, ACHN and KPK-1 were evaluated using western blot analysis, while galectin-3 expression in CC-RCC tissues and normal parenchyma were measured by real-time PCR and immunohistochemistry. We found that galectin-3 was overexpressed in the Caki-1, Caki-2, A704, ACHN and KPK-1 cell lines and that the expression level in CC-RCC was also significantly higher than that in renal parenchyma obtained from the same patient samples (p=0.039). Galectin-3 expression in CC-RCC with distant metastasis was also significantly higher than that in CC-RCC without distant metastasis (p=0.045). In conclusion, we revealed that galectin-3 is highly expressed in CC-RCC, especially in CC-RCC with distant metastasis, suggesting that galectin-3 may serve as a novel target molecule for predicting CC-RCC metastasis. J. Med. Invest. 57: 152-157, February, 2010

1 January 2008 in The Journal of Medical Investigation
Verified
Journal Article
Open access
PDF file
STShuji Tanimoto
Shuji Tanimoto
TFTomoharu Fukumori
Tomoharu Fukumori
GEGad El-Moula
Gad El-Moula
SAShiirevnyamba Avirmed
Shiirevnyamba Avirmed
SKShinichiro Kinouchi
Shinichiro Kinouchi
HKHiro-Omi Kanayama
Hiro-Omi Kanayama
No adequate serum predictive biomarker currently exists, which can identify the activity of renal cell carcinoma (RCC). We investigate the association of serum hepatocyte growth factor (HGF) and serum vascular endothelial growth factor (VEGF) levels with clinicopathologic parameters in untreated clear cell RCC patients. We measured serum levels of HGF and VEGF in 45 patients with untreated clear cell RCC and 45 healthy controls using an enzyme-linked immunosorbent assay (ELISA). Patients with clear cell RCC had significantly higher serum HGF and VEGF concentrations than healthy subjects: median, 1070.7 versus 728.3 pg/ml (p1150 pg/ml) was significantly reduced compared to patients with low serum HGF concentrations (p=0.0044). In patients with nuclear grade 2 or high stage RCC, the higher serum HGF group exhibited significantly lower cause-specific survival (p=0.0087 and p< 0.05, respectively). No significant difference was observed between serum VEGF levels and cause-specific survival rate. Serum HGF might be a diagnostic and prognostic indicator in clear cell RCC, especially for patients with grade 2 or high stage RCC. J. Med. Invest. 55: 106-111, February, 2008

1 February 2010 in Urology
Verified
Journal Article
Closed access
TKTakahiro Koizumi
Takahiro Koizumi
HNHiroyoshi Nakatsuji
Hiroyoshi Nakatsuji
TFTomoya Fukawa
Tomoya Fukawa
SAShiirevnyamba Avirmed
Shiirevnyamba Avirmed
TFTomoharu Fukumori
Tomoharu Fukumori
HKHiroomi Kanayama
Hiroomi Kanayama

4 January 2011 in British Journal of Cancer
Verified
Journal Article
Open access
SAShiirevnyamba Avirmed
Shiirevnyamba Avirmed
TTT Takahashi
T Takahashi
HSH Shan
H Shan
HOH Ogawa
H Ogawa
SYS Yano
S Yano
HUH Uehara
H Uehara
Background: Methods: Results: Conclusion:

1 August 2021 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
SAShiirevnyamba Avirmed
Shiirevnyamba Avirmed
Yerkhanat KhuanbaiYerkhanat Khuanbai
Yerkhanat Khuanbai
ASAmarsaikhan Sanjaajamts
Amarsaikhan Sanjaajamts
BSBaasansuren Selenge
Baasansuren Selenge
BDBayan-Undur Dagvadorj
Bayan-Undur Dagvadorj
MOMakoto Ohashi
Makoto Ohashi
Objectives: Tobacco smoking is the predominant risk factor for bladder cancer as it contains cancer-causing chemicals. However, genetic factors may play important role in response towards chemical carcinogens. In this study we aim to investigate genetic polymorphisms of glutathione S-transferase M1 (GSTM1) and N-acetyltransferase 2 (NAT2) as determinants of bladder cancer risk, independently and in combination with tobacco use in the Mongolian population. Materials and Methods: The current study was a hospital-based case-control study including 60 histologically confirmed bladder cancer patients and 60 cancer-free controls. PCR-RFLP assay was used to determine the presence of GSTM1 and NAT2 polymorphisms in bladder cancer patients and controls. GSTM1 and NAT2 were tested using binary logistical regression analysis with adjustment or stratification according to the smoking. Results: There were 46 men and 14 women diagnosed with bladder cancer, with mean age was 58±4. The controls included 37 men and 23 women with a mean age of 57±3. The frequency of GSTM1 null genotype was higher in controls (71.67%) than in bladder cancer patients (58.33%) without statistical significance (OR=0.5534; 95% CI=0.2586-1.1843), (p=0.128). The NAT2 low acetylator phenotype was more common in patients with bladder cancer (15%) than in controls (5%). Furthermore, individuals with NAT2 low acetylator phenotype had a nearly 3.35-fold increased risk to develop bladder cancer (OR=3.35; 95% CI=0.8604-13.0657), (p=0.081) while the risk was even higher when combined with null GSTM1 genotype (OR=4; 95% CI=0.4459-37.5308), (p=0.213) but there was no statistical significance. Prevalence of smoking in bladder cancer patients was higher than controls and increased significantly the risk of bladder cancer (OR=8.31; 95% CI=3.66-18.88). Smokers with GSTM1 null genotype were at 5-fold higher risk of bladder cancer (OR=5.0; 95% CI=1.55-16.16), (p=0.007) while NAT2 low acetylator phenotype increased bladder cancer risk by 20-fold (OR=20.5; 95% CI=2.33-80.86), (p=0.006). Conclusion: The current study shows that tobacco smokers with the NAT2 low acetylator phenotype and GSTM1 null genotype have the highest risk of bladder cancer in the Mongolian population.